Contact us

877-469-1TRM
424-208-8866

Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer (SOPHIA)

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients With HER2+ Metastatic Breast Cancer Who Have Received Two Prior Anti-HER2 Therapies and Require Systemic Treatment.

For more information, please visit ClinicalTrials.gov

Patient Population Investigational Product(s) Phase Status
HER-2 Positive Breast Cancer Margetuximab III Open and Accruing